[HTML][HTML] Characterization of the myeloid-specific CD11b promoter
HL Pahl, AG Rosmarin, DG Tenen - Blood, 1992 - Elsevier
HL Pahl, AG Rosmarin, DG Tenen
Blood, 1992•ElsevierThe CD11b/CD18 heterodimeric surface antigen is expressed exclusively on human
monocytes, macrophages, granulocytes, and natural killer cells. During differentiation of
myeloid cell lines, CD11b steady state messenger RNA levels increase significantly; we
show here that CDllb transcription rates increase commensurately. A 1.7-kb fragment of
CD11b 5'flanking sequence directs expression of a reporter gene specifically in myeloid cell
lines. Deletion analysis localizes elements directing high levels of tissue-specific reporter …
monocytes, macrophages, granulocytes, and natural killer cells. During differentiation of
myeloid cell lines, CD11b steady state messenger RNA levels increase significantly; we
show here that CDllb transcription rates increase commensurately. A 1.7-kb fragment of
CD11b 5'flanking sequence directs expression of a reporter gene specifically in myeloid cell
lines. Deletion analysis localizes elements directing high levels of tissue-specific reporter …
The CD11b/CD18 heterodimeric surface antigen is expressed exclusively on human monocytes, macrophages, granulocytes, and natural killer cells. During differentiation of myeloid cell lines, CD11b steady state messenger RNA levels increase significantly; we show here that CDllb transcription rates increase commensurately. A 1.7-kb fragment of CD11b 5’ flanking sequence directs expression of a reporter gene specifically in myeloid cell lines. Deletion analysis localizes elements directing high levels of tissue-specific
reporter gene expression to the 412 bp proximal to the transcriptional start site. This sequence contains two consensus binding sites for Sp1, a GATA motif, and a purine-rich sequence that presents potential binding sites for members of the ets family of genes. Analysis of this promoter should result in the isolation of myeloid-specific transcription factors and the development of methods to direct the myeloid-specific expression of heterologous genes. © 1992 by The American Society of Hematology. 0006-497119217904-0036$3.0010
Elsevier